Evidence mapPaperPMID 42014041Full record

ReviewThe Journal of clinical endocrinology and metabolism2026

Acromegaly complications: an update.

Andrea Giustina, Maria Fleseriu

Abstract readReview
In one paragraph

Review in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Andrea GiustinaInstitute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS San Raffaele Hospital, Milan 20132, Italy.ORCID 0000-0001-6783-3398
Maria FleseriuPituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0000-0001-9284-6289

Funding

Crinetics Pharmaceuticals, Inc
6 · The paper itself

Abstract

contextAppropriate diagnosis and treatment of comorbidities is key to managing acromegaly given their adverse clinical impact on quality of life and survival; thus, it is important to increase overall awareness of complications and their individualized management. EVIDENCE: This review examines the current literature on pathophysiology, diagnosis, and clinical presentation of acromegaly complications, as well as impact of acromegaly therapy and current goals for treatment outcomes of these morbidities.

conclusionWe focus on the most relevant acromegaly comorbidities including cardiorespiratory, metabolic, bone, and oncologic complications. Selected complications that may determine pharmacologic choices are also evaluated.

Indexed as

AcromegalyCardiovascular DiseasesComorbidityHumansNeoplasmsacromegalycancercardiomyopathydiabetes mellitushypertensionvertebral fractures

Identifiers

PMID42014041
PMCPMC13235294

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.